Jason Gerberry
Stock Analyst at B of A Securities
(3.67)
# 797
Out of 4,984 analysts
160
Total ratings
56.52%
Success rate
4.84%
Average return
Main Sectors:
Stocks Rated by Jason Gerberry
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AMPH Amphastar Pharmaceuticals | Maintains: Neutral | $28 → $32 | $26.98 | +18.61% | 2 | Aug 26, 2025 | |
| IMVT Immunovant | Maintains: Buy | $33 → $30 | $15.11 | +98.61% | 6 | Aug 12, 2025 | |
| BHVN Biohaven | Maintains: Buy | $50 → $49 | $14.69 | +233.56% | 2 | Aug 12, 2025 | |
| AXSM Axsome Therapeutics | Maintains: Buy | $173 → $176 | $116.62 | +50.92% | 6 | Aug 5, 2025 | |
| PROK ProKidney | Downgrades: Underperform | $3 → $1 | $2.53 | -60.47% | 4 | Jun 30, 2025 | |
| LQDA Liquidia | Maintains: Buy | $25 → $23 | $25.00 | -8.00% | 2 | Jun 11, 2025 | |
| EXEL Exelixis | Maintains: Neutral | $45 → $46 | $40.44 | +13.75% | 3 | Jun 5, 2025 | |
| TEVA Teva Pharmaceutical Industries | Maintains: Buy | $20 → $22 | $18.38 | +19.70% | 14 | May 8, 2025 | |
| PCVX Vaxcyte | Maintains: Buy | $157 → $137 | $30.89 | +343.58% | 9 | Apr 1, 2025 | |
| VTRS Viatris | Maintains: Underperform | $11 → $10 | $9.62 | +3.95% | 3 | Feb 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $30 | $20.02 | +49.85% | 2 | Jan 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $84 → $100 | $76.42 | +30.86% | 4 | Nov 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $20 → $24 | $4.09 | +486.80% | 1 | Sep 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $67 → $68 | $61.11 | +11.27% | 5 | Jul 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $21 → $20 | $17.40 | +14.94% | 3 | Jun 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $41 → $31 | $32.19 | -3.70% | 6 | Apr 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $600 → $550 | $6.41 | +8,480.34% | 3 | Mar 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $27 → $29 | $27.87 | +4.05% | 9 | Jan 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $29 → $37 | $29.13 | +27.02% | 2 | Jan 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $52 → $56 | $36.70 | +52.59% | 2 | Jan 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $30 | $32.06 | -6.43% | 2 | Jan 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $204 → $217 | $129.54 | +67.52% | 5 | Aug 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $100 → $50 | $11.14 | +348.83% | 6 | Aug 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $450 → $500 | $760.13 | -34.22% | 15 | May 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $9 | $1.13 | +696.46% | 1 | Dec 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $37 → $25 | $10.45 | +139.23% | 3 | Oct 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $45 → $5 | $1.82 | +174.73% | 2 | Dec 2, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $27 | $6.83 | +295.31% | 4 | Mar 24, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $20 | $1.36 | +1,376.01% | 1 | Jul 16, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $170 → $100 | $4.40 | +2,172.73% | 1 | Jul 15, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Neutral | $95 | $220.81 | -56.98% | 10 | May 18, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Buy | $60 | $46.15 | +30.01% | 7 | Oct 17, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Neutral | $37 | $24.05 | +53.85% | 4 | Oct 17, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Neutral | $90 | $81.14 | +10.92% | 11 | Oct 17, 2019 |
Amphastar Pharmaceuticals
Aug 26, 2025
Maintains: Neutral
Price Target: $28 → $32
Current: $26.98
Upside: +18.61%
Immunovant
Aug 12, 2025
Maintains: Buy
Price Target: $33 → $30
Current: $15.11
Upside: +98.61%
Biohaven
Aug 12, 2025
Maintains: Buy
Price Target: $50 → $49
Current: $14.69
Upside: +233.56%
Axsome Therapeutics
Aug 5, 2025
Maintains: Buy
Price Target: $173 → $176
Current: $116.62
Upside: +50.92%
ProKidney
Jun 30, 2025
Downgrades: Underperform
Price Target: $3 → $1
Current: $2.53
Upside: -60.47%
Liquidia
Jun 11, 2025
Maintains: Buy
Price Target: $25 → $23
Current: $25.00
Upside: -8.00%
Exelixis
Jun 5, 2025
Maintains: Neutral
Price Target: $45 → $46
Current: $40.44
Upside: +13.75%
Teva Pharmaceutical Industries
May 8, 2025
Maintains: Buy
Price Target: $20 → $22
Current: $18.38
Upside: +19.70%
Vaxcyte
Apr 1, 2025
Maintains: Buy
Price Target: $157 → $137
Current: $30.89
Upside: +343.58%
Viatris
Feb 28, 2025
Maintains: Underperform
Price Target: $11 → $10
Current: $9.62
Upside: +3.95%
Jan 9, 2025
Reiterates: Buy
Price Target: $30
Current: $20.02
Upside: +49.85%
Nov 6, 2024
Maintains: Buy
Price Target: $84 → $100
Current: $76.42
Upside: +30.86%
Sep 10, 2024
Maintains: Buy
Price Target: $20 → $24
Current: $4.09
Upside: +486.80%
Jul 23, 2024
Maintains: Buy
Price Target: $67 → $68
Current: $61.11
Upside: +11.27%
Jun 11, 2024
Maintains: Buy
Price Target: $21 → $20
Current: $17.40
Upside: +14.94%
Apr 1, 2024
Downgrades: Underperform
Price Target: $41 → $31
Current: $32.19
Upside: -3.70%
Mar 25, 2024
Maintains: Buy
Price Target: $600 → $550
Current: $6.41
Upside: +8,480.34%
Jan 2, 2024
Maintains: Neutral
Price Target: $27 → $29
Current: $27.87
Upside: +4.05%
Jan 2, 2024
Maintains: Buy
Price Target: $29 → $37
Current: $29.13
Upside: +27.02%
Jan 2, 2024
Maintains: Buy
Price Target: $52 → $56
Current: $36.70
Upside: +52.59%
Jan 2, 2024
Downgrades: Underperform
Price Target: $30
Current: $32.06
Upside: -6.43%
Aug 10, 2023
Maintains: Buy
Price Target: $204 → $217
Current: $129.54
Upside: +67.52%
Aug 8, 2023
Downgrades: Underperform
Price Target: $100 → $50
Current: $11.14
Upside: +348.83%
May 24, 2023
Maintains: Buy
Price Target: $450 → $500
Current: $760.13
Upside: -34.22%
Dec 12, 2022
Downgrades: Underperform
Price Target: $9
Current: $1.13
Upside: +696.46%
Oct 14, 2022
Downgrades: Underperform
Price Target: $37 → $25
Current: $10.45
Upside: +139.23%
Dec 2, 2021
Downgrades: Underperform
Price Target: $45 → $5
Current: $1.82
Upside: +174.73%
Mar 24, 2021
Downgrades: Underperform
Price Target: $27
Current: $6.83
Upside: +295.31%
Jul 16, 2020
Initiates: Neutral
Price Target: $20
Current: $1.36
Upside: +1,376.01%
Jul 15, 2020
Downgrades: Neutral
Price Target: $170 → $100
Current: $4.40
Upside: +2,172.73%
May 18, 2020
Reinstates: Neutral
Price Target: $95
Current: $220.81
Upside: -56.98%
Oct 17, 2019
Reinstates: Buy
Price Target: $60
Current: $46.15
Upside: +30.01%
Oct 17, 2019
Reinstates: Neutral
Price Target: $37
Current: $24.05
Upside: +53.85%
Oct 17, 2019
Reinstates: Neutral
Price Target: $90
Current: $81.14
Upside: +10.92%